BCM
MRNA icon

Bayesian Capital Management’s Moderna MRNA Stock Holding History

Bayesian Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,900
Closed -$1.16M – 708
2025
Q2 		$1.16M Buy
+41,900
New +$1.1M 0.18% 161
2024
Q4 		– Sell
-5,900
Closed -$394K – 872
2024
Q3 		$394K Buy
+5,900
New +$542K 0.05% 424
2023
Q3 		– Sell
-2,548
Closed -$310K – 874
2023
Q2 		$310K Sell
2,548
-43,400
-94% -$5.79M 0.03% 526
2023
Q1 		$7.06M Buy
45,948
+35,300
+332% +$5.82M 0.87% 7
2022
Q4 		$1.91M Sell
10,648
-15,752
-60% -$2.58M 0.28% 67
2022
Q3 		$3.12M Buy
+26,400
New +$4.01M 0.63% 22
2021
Q2 		– Sell
-56,100
Closed -$7.35M – 556
2021
Q1 		$7.35M Buy
+56,100
New +$8.13M 1.69% 5
2020
Q4 		– Sell
-58,406
Closed -$4.13M – 594
2020
Q3 		$4.13M Buy
+58,406
New +$4.07M 1.01% 9
2020
Q2 		– Sell
-15,380
Closed -$461K – 680
2020
Q1 		$461K Buy
+15,380
New +$354K 0.1% 313

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bayesian Capital Management's MRNA Position: Q3 2025 in Review

Bayesian Capital Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 41,900 shares — an estimated $1.16M sold.

Bayesian Capital Management first reported a position in MRNA in Q1 2020 and held it in 9 quarters. The position peaked at $7.35M in Q1 2021. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Bayesian Capital Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 41,900 Moderna shares in Q3 2025, an estimated $1.16M.
  • Bayesian Capital Management first reported a position in Moderna in Q1 2020 and held it in 9 quarters.
  • Bayesian Capital Management's Moderna position peaked at $7.35M in Q1 2021.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.